DK2714710T3 - Fremgangsmåde til fremstilling af estetrol-mellemprodukter - Google Patents
Fremgangsmåde til fremstilling af estetrol-mellemprodukter Download PDFInfo
- Publication number
- DK2714710T3 DK2714710T3 DK12729054.2T DK12729054T DK2714710T3 DK 2714710 T3 DK2714710 T3 DK 2714710T3 DK 12729054 T DK12729054 T DK 12729054T DK 2714710 T3 DK2714710 T3 DK 2714710T3
- Authority
- DK
- Denmark
- Prior art keywords
- formula
- compound
- group
- process according
- alkyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J75/00—Processes for the preparation of steroids in general
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
- C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0059—Estrane derivatives substituted in position 17 by a keto group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
- C07J13/005—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 16 (17)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (14)
1. Fremgangsmåde til fremstilling af en forbindelse med formel (I)
(I) hvilken fremgangsmåde omfatter følgende trin a) omsætning af en forbindelse med formel (II) med et acylerings- eller et sily-leringsmiddel til dannelse af en forbindelse med formel (III), hvor P1 og P2 hver især uafhængigt er en beskyttelsesgruppe, som er valgt blandt R2-Si-R3R4 eller R1CO-, hvor R1 er en gruppe, som er valgt blandt Ci_6alkyl eller C3-6cycloalkyl, idet hver gruppe eventuelt er substitueret med én eller flere substituenter, som uafhængigt er valgt blandt fluor eller Ci^alkyl; R2, R3 og R4 hver især uafhængigt er en gruppe, som er valgt blandt Ci_6alkyl eller phenyl, idet hver gruppe eventuelt er substitueret med én eller flere substituenter, som uafhængigt er valgt blandt fluor eller Ci^alkyl;
(II) (III) b) omsætning af forbindelsen med formel (III) i nærværelse af palladiumacetat eller palladiumchlorid til dannelse af en forbindelse med formel (IV); og
(IV) c) omsætning af forbindelsen med formel (IV) med et reduktionsmiddel til dannelse af en forbindelse med formel (I).
2. Fremgangsmåde ifølge krav 1, hvor P1 er R1CO-.
3. Fremgangsmåde ifølge krav 1, hvor P1 er R2-Si-R3R4.
4. Fremgangsmåde ifølge krav 3, hvor P2 er R2-Si-R3R4.
5. Fremgangsmåde ifølge et hvilket som helst af kravene 1 til 3, hvor P2 er R1CO-.
6. Fremgangsmåde ifølge krav 5, hvor trin (a) omfatter følgende trin: (a1) beskyttelse af hydroxyl i en forbindelse med formel (II) med et silyleringsmiddel til dannelse af en forbindelse med formel (Ila), hvor P1 harden samme betydning som defineret i krav 3; og
(Ila) (a2) beskyttelse af ketonen i en forbindelse med formel (Ila) i nærværelse af et acyle-ringsmiddel til dannelse af en forbindelse med formel (III).
7. Fremgangsmåde ifølge et hvilket som helst af kravene 1 til 3, 5 og 6, hvor acyle-ringsmidlet er C2-6alkenylCi-6alkanoat eller C2-6alkenylC3-6cycloalkanoat.
8. Fremgangsmåde ifølge et hvilket som helst af kravene 1,3 til 7, hvor silyleringsmid-let er valgt fra gruppen omfattende Ci-6alkylsilylchlorid, Ci-6alkylsilyltriflat, phenylsilyl-chlorid, phenylsilyltriflat, Ci-6alkylphenylsilylchlorid, Ci-6alkylphenylsilyltriflat, idet hver gruppe eventuelt er substitueret med én eller flere substituenter, som uafhængigt er valgt blandt fluor eller Ci.4alkyl.
9. Fremgangsmåde ifølge et hvilket som helst af kravene 1 til 8, hvor trin (b) udføres i nærværelse af et Ci.6alkylencarbonat med formel Rb-0-C0-0-Ra, hvor Ra er Ci.6-alkyl, og Rb er C2.6-alkenyl, og en organotinforbindelse.
10. Fremgangsmåde ifølge et hvilket som helst af kravene 1 til 9, hvor palladiumacetatet eller palladiumchloridet er til stede i støkiometriske mængder.
11. Fremgangsmåde ifølge et hvilket som helst af kravene 1 til 9, hvor reaktionen udføres med palladiumacetat eller palladiumchlorid, som er til stede i katalytiske eller sub-støkiometriske mængder, idet reaktionen fortrinsvis udføres i en oxygenatmosfære.
12. Fremgangsmåde ifølge et hvilket som helst af kravene 1 til 11, hvor reduktionsmidlet i trin (c) er valgt fra gruppen af metalhydridforbindelser.
13. Fremgangsmåde ifølge krav 12, hvor metalhydridforbindelsen er valgt fra gruppen omfattende NaBH4/CeCI3, LiAIH4, NaBH4, NaBH(OAc)3 og ZnBH4.
14. Fremgangsmåde til fremstilling af estetrol, hvilken fremgangsmåde omfatter fremstilling af en forbindelse med formel (I) ved en fremgangsmåde ifølge et hvilket som helst af kravene 1 til 13 og yderligere omsætning af en forbindelse med formel (I) til dannelse af estetrol.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161492300P | 2011-06-01 | 2011-06-01 | |
EP11168561 | 2011-06-01 | ||
PCT/EP2012/060447 WO2012164096A1 (en) | 2011-06-01 | 2012-06-01 | Process for the production of estetrol intermediates |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2714710T3 true DK2714710T3 (da) | 2016-06-27 |
Family
ID=45003353
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK12729054.2T DK2714710T3 (da) | 2011-06-01 | 2012-06-01 | Fremgangsmåde til fremstilling af estetrol-mellemprodukter |
Country Status (24)
Country | Link |
---|---|
US (1) | US11053274B2 (da) |
EP (1) | EP2714710B1 (da) |
JP (2) | JP6425540B2 (da) |
KR (1) | KR101994805B1 (da) |
CN (2) | CN103703014A (da) |
AU (1) | AU2012264602B2 (da) |
BR (1) | BR112013030830B1 (da) |
CA (1) | CA2835981C (da) |
CY (1) | CY1118150T1 (da) |
DK (1) | DK2714710T3 (da) |
EA (1) | EA023991B1 (da) |
ES (1) | ES2579175T3 (da) |
HR (1) | HRP20160692T2 (da) |
HU (1) | HUE029252T2 (da) |
ME (1) | ME02454B (da) |
MX (1) | MX341561B (da) |
PL (1) | PL2714710T3 (da) |
PT (1) | PT2714710T (da) |
RS (1) | RS54880B1 (da) |
SG (1) | SG195118A1 (da) |
SI (1) | SI2714710T1 (da) |
SM (1) | SMT201600206B (da) |
WO (1) | WO2012164096A1 (da) |
ZA (1) | ZA201308446B (da) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2714712T3 (da) | 2011-06-01 | 2016-12-05 | Estetra Sprl | Fremgangsmåde til fremstilling af estetrol-mellemprodukter |
HUE029252T2 (en) | 2011-06-01 | 2017-02-28 | Estetra Sprl | Process for the preparation of intermediates of estetrol |
EP2383279A1 (en) | 2011-07-19 | 2011-11-02 | Pantarhei Bioscience B.V. | Process for the preparation of estetrol |
MX348917B (es) | 2011-10-07 | 2017-07-04 | Estetra Sprl | Proceso para la producción de estetrol. |
KR102662025B1 (ko) | 2015-06-18 | 2024-05-02 | 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 | 에스테트롤 성분을 함유하는 구강분해성 투여 단위 |
RS61812B1 (sr) | 2015-06-18 | 2021-06-30 | Estetra Sprl | Oralno-disperzibilna tableta koja sadrži estetriol |
MD3310346T2 (ro) | 2015-06-18 | 2021-06-30 | Estetra Sprl | Comprimată orodispersabilă ce conține estetrol |
AU2016280863B2 (en) | 2015-06-18 | 2021-04-01 | Estetra Srl | Orodispersible dosage unit containing an estetrol component |
CN105837424A (zh) * | 2016-03-31 | 2016-08-10 | 常州大学 | 一种1-氯-3-甲基-3-丁烯-2-酮的合成方法 |
CA3178291A1 (en) | 2016-08-05 | 2018-04-12 | Estetra Srl | Method for the management of dysmenorrhea and menstrual pain |
JP6935766B2 (ja) | 2018-02-15 | 2021-09-15 | 日本精工株式会社 | スピンドル装置 |
JOP20200260A1 (ar) | 2018-04-19 | 2019-10-19 | Estetra Sprl | مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث |
TWI801561B (zh) | 2018-04-19 | 2023-05-11 | 比利時商依思特拉私人有限責任公司 | 化合物及其用於緩解絕經相關症狀的用途 |
MX2022003688A (es) | 2019-09-27 | 2022-04-26 | Ind Chimica Srl | Proceso para preparar (15alfa,16alfa,17beta)-estra-1,3,5(10)-trien o-3,15,16,17-tetrol (estetrol) e intermedios de dicho proceso. |
IT201900021879A1 (it) | 2019-11-22 | 2021-05-22 | Ind Chimica Srl | PROCESSO PER LA PREPARAZIONE DI (15α,16α,17β)-ESTRA-1,3,5(10)-TRIENE-3,15,16,17-TETROLO (ESTETROLO) ED INTERMEDI DI DETTO PROCESSO |
IT201900017414A1 (it) | 2019-09-27 | 2021-03-27 | Ind Chimica Srl | Processo per la preparazione di (15α,16α,17β)-estra-1,3,5(10)-triene-3,15,16,17-tetrolo (Estetrolo) ed intermedi di detto processo |
WO2023021026A1 (en) | 2021-08-17 | 2023-02-23 | Aspen Oss B.V. | A synthetic pathway to estra-1,3,5(10)-triene-3,15a,16a,17b-tetrol |
GB2626482A (en) | 2021-10-01 | 2024-07-24 | Ind Chimica Srl | Process for preparing (15alpha,16alpha,17eta)-estra-1,3,5-(10)-triene-3,15,16,17-tetrol(estetrol) monohydrate |
Family Cites Families (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE144266C (da) | ||||
US3138588A (en) | 1962-08-24 | 1964-06-23 | American Home Prod | 17-ketals of estrone and derivatives thereof |
US3177206A (en) | 1963-03-07 | 1965-04-06 | American Home Prod | Selective bromination of a-ring aromatic 17-ketalized steroids |
US3433785A (en) | 1966-07-11 | 1969-03-18 | Sterling Drug Inc | 15,16-disubstituted aromatic steroids,intermediates and processes |
US3673180A (en) | 1970-06-18 | 1972-06-27 | Merck & Co Inc | 19-nor-6,6-ethylene-20-spiroxenes |
US4792620A (en) | 1983-10-14 | 1988-12-20 | Bp Chemicals Limited | Carbonylation catalysts |
US4739078A (en) | 1984-02-17 | 1988-04-19 | The Upjohn Company | Use of borohydride-salt lanthanide salt reagents for stereo selective reduction of C-15-keto prostaglandin precursors |
IE60780B1 (en) | 1987-01-23 | 1994-08-10 | Akzo Nv | New 11-aryl steroid derivatives |
DE3710728A1 (de) | 1987-03-31 | 1988-10-13 | Schering Ag | Verfahren zur herstellung von 17(alpha)-ethinyl-17ss-hydroxy-18-methyl-4,15-estradien-3-on und die neuen zwischenprodukte fuer dieses verfahren |
US5073374A (en) | 1988-11-30 | 1991-12-17 | Schering Corporation | Fast dissolving buccal tablet |
US5340586A (en) | 1991-04-12 | 1994-08-23 | University Of Southern California | Methods and formulations for use in treating oophorectomized women |
JPH07101977A (ja) | 1993-10-05 | 1995-04-18 | Kureha Chem Ind Co Ltd | ホルモン作用を軽減した新規なエストラジオール誘導体及びその増殖因子阻害剤 |
WO1997004752A1 (en) | 1995-07-26 | 1997-02-13 | Duramed Pharmaceuticals, Inc. | Pharmaceutical compositions of conjugated estrogens and methods for their use |
US6117446A (en) | 1999-01-26 | 2000-09-12 | Place; Virgil A. | Drug dosage unit for buccal administration of steroidal active agents |
TW548277B (en) | 1999-07-16 | 2003-08-21 | Akzo Nobel Nv | Orally active androgens |
US20020132801A1 (en) | 2001-01-11 | 2002-09-19 | Schering Aktiengesellschaft | Drospirenone for hormone replacement therapy |
PT1390040E (pt) | 2001-05-18 | 2007-04-30 | Pantarhei Bioscience Bv | Composição farmacêutica para ser utilizado na terapia hormonal de substituição. |
EP1260225A1 (en) | 2001-05-18 | 2002-11-27 | Pantarhei Bioscience B.V. | A pharmaceutical composition for use in hormone replacement therapy |
DK1390042T3 (da) | 2001-05-23 | 2008-03-31 | Pantarhei Bioscience Bv | System for administration af et lægemiddel omfattende tetrahydroxyleret östrogen til anvendelse i hormonal svangerskabsforebyggelse |
US7871995B2 (en) | 2001-05-23 | 2011-01-18 | Pantarhei Bioscience B.V. | Drug delivery system comprising a tetrahydroxylated estrogen for use in hormonal contraception |
WO2003018026A1 (en) | 2001-08-31 | 2003-03-06 | Pantarhei Bioscience B.V. | Use of estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy |
US8026228B2 (en) | 2001-11-15 | 2011-09-27 | Pantarhei Bioscience B.V. | Estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy |
US6723348B2 (en) | 2001-11-16 | 2004-04-20 | Ethypharm | Orodispersible tablets containing fexofenadine |
HU227198B1 (en) | 2001-11-27 | 2010-10-28 | Richter Gedeon Nyrt | Pharmaceutical composition for emergency contraception containing levonorgestrel |
MXPA04008185A (es) | 2002-02-21 | 2004-11-26 | Schering Ag | Composiciones farmaceuticas que comprenden uno o mas esteroides, uno o mas componentes de tetrahidrofolato y vitamina b12. |
US20050147670A1 (en) | 2002-05-29 | 2005-07-07 | Impax Laboratories Inc. | Oral disintegrating dosage forms |
CA2489270C (en) | 2002-06-11 | 2012-08-07 | Pantarhei Bioscience B.V. | A method of treating human skin and a skin care composition for use in such a method |
CN1691947B (zh) | 2002-06-11 | 2011-11-23 | 潘塔希生物科学股份有限公司 | ***成分在制备用于治疗或预防免疫介导的疾病中的应用以及包含所述***成分的药物组合物 |
ES2299730T3 (es) | 2002-07-12 | 2008-06-01 | Pantarhei Bioscience B.V. | Composicion farmaceutica que comprende derivados de estetrol para el uso en la terapia del cancer. |
WO2004037269A1 (en) | 2002-10-23 | 2004-05-06 | Pantarhei Bioscience B.V. | Pharmaceutical compositions comprising estetrol derivatives for use in cancer therapy |
ES2346053T3 (es) * | 2002-11-08 | 2010-10-08 | Pantarhei Bioscience B.V. | Sintesis de esterol a traves de esteroides derivados de estrona. |
SI1624878T1 (sl) | 2003-05-22 | 2007-02-28 | Pantarhei Bioscience Bv | Uporaba sestavkov, ki obsegajo estrogensko komponento, za zdravljenje in preprecevanje muskuloskeletne bolecine |
CN101189251B (zh) | 2005-05-26 | 2012-09-12 | 索尔瓦药物有限公司 | 17β-HSD1和STS抑制剂 |
EP2077322B1 (de) | 2005-07-25 | 2010-08-25 | RiboxX GmbH | Verfahren und Kit zur Amplifikation von heteropolymerer oder poly(C)- RNA |
US20070048369A1 (en) | 2005-08-26 | 2007-03-01 | National Starch And Chemical Investment Holding Corporation | Mucosal delivery tablet |
EP1971344B1 (en) | 2006-01-09 | 2010-09-22 | Pantarhei Bioscience B.V. | A method of treating an acute vascular disorder |
MX2008014941A (es) | 2006-06-08 | 2008-12-10 | Warner Chilcott Co Inc | Metodos para administrar formas de dosificacion solida de etinil estradiol y profarmacos del mismo con biodisponibilidad mejorada. |
US20070286819A1 (en) | 2006-06-08 | 2007-12-13 | Warner Chilcott Company, Inc. | Methods to administer ethinyl estradiol and prodrugs thereof with improved bioavailability |
US20080113953A1 (en) | 2006-06-08 | 2008-05-15 | Warner Chilcott Company, Inc. | Methods to administer solid dosage forms of ethinyl estradiol and prodrugs thereof with improved bioavailability |
GB0621926D0 (en) | 2006-11-03 | 2006-12-13 | Medlock Medical Ltd | Multi directional stretch tubular bandages |
JP2010511062A (ja) | 2006-11-29 | 2010-04-08 | ワイス エルエルシー | エストロゲン/sermおよびエストロゲン/プロゲスチン二層錠剤 |
US7867515B2 (en) | 2006-12-20 | 2011-01-11 | TEVA Woman's Health, Inc. | Orally disintegrating solid dosage forms comprising progestin and methods of making and use thereof |
CN101583363B (zh) * | 2007-01-08 | 2013-08-21 | 潘塔希生物科学股份有限公司 | 治疗或预防雌性哺乳动物不育症的方法和此类方法中使用的药物试剂盒 |
RU2009125413A (ru) | 2007-01-12 | 2011-02-20 | Вайет (Us) | Композиции таблетка-в-таблетке |
US8367647B2 (en) | 2007-06-21 | 2013-02-05 | Pantarhei Bioscience B.V. | Treatment of meconium aspiration syndrome with estrogens |
ATE533492T1 (de) | 2007-07-19 | 2011-12-15 | Pantarhei Bioscience Bv | Behandlung oder prävention von hypertensiven erkrankungen in der schwangerschaft oder von wachstumsverzögerung des foeten |
CN101541725B (zh) | 2007-08-31 | 2013-08-28 | 国立大学法人名古屋大学 | 羰基化合物的制造方法和用于制造羰基化合物的氧化促进剂 |
EP2077272A1 (en) | 2007-12-21 | 2009-07-08 | Affibody AB | Polypeptide libraries with a predetermined scaffold |
EP2077273B1 (en) | 2007-12-31 | 2011-09-14 | Animal Technology Institute Taiwan | Methods for separating casein from soluble proteins in a composition |
US20110250274A1 (en) | 2008-09-19 | 2011-10-13 | Shaked Ze Ev | Estriol formulations |
DE102009007771B4 (de) | 2009-02-05 | 2012-02-16 | Bayer Schering Pharma Aktiengesellschaft | Bukkales Applikationssystem, 17α-Estradiol enthaltend |
CN102058604A (zh) | 2009-11-17 | 2011-05-18 | 北京万全阳光医学技术有限公司 | 一种含有地诺孕素和戊酸***的药物组合物及其制备方法 |
US9603860B2 (en) | 2010-07-28 | 2017-03-28 | Laboratorios Leon Farma Sa | Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same |
HUE029252T2 (en) | 2011-06-01 | 2017-02-28 | Estetra Sprl | Process for the preparation of intermediates of estetrol |
DK2714712T3 (da) | 2011-06-01 | 2016-12-05 | Estetra Sprl | Fremgangsmåde til fremstilling af estetrol-mellemprodukter |
HUE025350T2 (en) | 2011-07-19 | 2016-02-29 | Pantarhei Bioscience Bv | Tablets containing dehydroepiandrosterone (DHEA) |
EP2383279A1 (en) | 2011-07-19 | 2011-11-02 | Pantarhei Bioscience B.V. | Process for the preparation of estetrol |
US9579329B2 (en) | 2011-08-11 | 2017-02-28 | Estetra S.P.R.L. | Use of estetrol as emergency contraceptive |
RU2633640C2 (ru) | 2011-09-16 | 2017-10-16 | Ферринг Б.В. | Быстрорастворимая фармацевтическая композиция |
MX348917B (es) | 2011-10-07 | 2017-07-04 | Estetra Sprl | Proceso para la producción de estetrol. |
US9808470B2 (en) | 2012-04-19 | 2017-11-07 | Universite De Liege | Estrogenic components for use in the treatment of neurological disorders |
EP2653163A1 (en) | 2012-04-19 | 2013-10-23 | Université de Liège | Estrogenic components for use in the treatment of neurological disorders |
WO2014159377A1 (en) | 2013-03-14 | 2014-10-02 | Teva Women's Health, Inc. | Compositions containing tanaproget and natural estrogens |
ES2624667T3 (es) | 2013-09-18 | 2017-07-17 | Crystal Pharma, S.A.U. | Procedimiento para la preparación de estetrol |
ES2655076T3 (es) | 2013-12-12 | 2018-02-16 | Donesta Bioscience B.V. | Unidad de dosificación sólida de desintegración oral con un componente de estetrol |
AU2016280863B2 (en) | 2015-06-18 | 2021-04-01 | Estetra Srl | Orodispersible dosage unit containing an estetrol component |
MD3310346T2 (ro) | 2015-06-18 | 2021-06-30 | Estetra Sprl | Comprimată orodispersabilă ce conține estetrol |
KR102662025B1 (ko) | 2015-06-18 | 2024-05-02 | 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 | 에스테트롤 성분을 함유하는 구강분해성 투여 단위 |
RS61812B1 (sr) | 2015-06-18 | 2021-06-30 | Estetra Sprl | Oralno-disperzibilna tableta koja sadrži estetriol |
-
2012
- 2012-06-01 HU HUE12729054A patent/HUE029252T2/en unknown
- 2012-06-01 EA EA201301316A patent/EA023991B1/ru unknown
- 2012-06-01 US US14/122,872 patent/US11053274B2/en active Active
- 2012-06-01 DK DK12729054.2T patent/DK2714710T3/da active
- 2012-06-01 EP EP12729054.2A patent/EP2714710B1/en active Active
- 2012-06-01 MX MX2013014045A patent/MX341561B/es active IP Right Grant
- 2012-06-01 CN CN201280026162.1A patent/CN103703014A/zh active Pending
- 2012-06-01 KR KR1020137031483A patent/KR101994805B1/ko active IP Right Grant
- 2012-06-01 RS RS20160478A patent/RS54880B1/sr unknown
- 2012-06-01 AU AU2012264602A patent/AU2012264602B2/en active Active
- 2012-06-01 JP JP2014513214A patent/JP6425540B2/ja active Active
- 2012-06-01 ES ES12729054.2T patent/ES2579175T3/es active Active
- 2012-06-01 WO PCT/EP2012/060447 patent/WO2012164096A1/en active Application Filing
- 2012-06-01 PT PT127290542T patent/PT2714710T/pt unknown
- 2012-06-01 ME MEP-2016-130A patent/ME02454B/me unknown
- 2012-06-01 CN CN201710354709.5A patent/CN107266514A/zh active Pending
- 2012-06-01 PL PL12729054T patent/PL2714710T3/pl unknown
- 2012-06-01 CA CA2835981A patent/CA2835981C/en active Active
- 2012-06-01 BR BR112013030830A patent/BR112013030830B1/pt active IP Right Grant
- 2012-06-01 SG SG2013086681A patent/SG195118A1/en unknown
- 2012-06-01 SI SI201230598A patent/SI2714710T1/sl unknown
-
2013
- 2013-11-11 ZA ZA2013/08446A patent/ZA201308446B/en unknown
-
2016
- 2016-06-15 CY CY20161100525T patent/CY1118150T1/el unknown
- 2016-06-17 HR HRP20160692TT patent/HRP20160692T2/hr unknown
- 2016-06-30 SM SM201600206T patent/SMT201600206B/it unknown
-
2017
- 2017-08-10 JP JP2017155801A patent/JP6479912B2/ja active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2714710T3 (da) | Fremgangsmåde til fremstilling af estetrol-mellemprodukter | |
AU2012264602A1 (en) | Process for the production of estetrol intermediates | |
KR102007874B1 (ko) | 에스테트롤 제조 방법 | |
ES2602227T3 (es) | Procedimiento para la preparación de estetrol | |
EP2714712B1 (en) | Process for the production of estetrol intermediates | |
NZ617613B2 (en) | Process for the production of estetrol intermediates | |
NZ617591B2 (en) | Process for the production of estetrol intermediates | |
NZ621973B2 (en) | Process for the production of estetrol |